AI Article Synopsis
- - The study assessed the effectiveness of a COVID-19 Sanofi booster vaccine by measuring neutralizing antibody levels in COVAIL recipients as a predictor of COVID-19 risk.
- - Higher levels of antibody titers were found to be associated with a lower risk of COVID-19, indicated by adjusted hazard ratios of 0.30 and 0.25 for different titer measurements.
- - An increase of 10-fold in the weighted average titer substantially reduced the risk, suggesting that higher antibody levels can offer better protection against the virus.
Article Abstract
For COVAIL recipients of a COVID-19 Sanofi booster vaccine, neutralizing antibody titers were assessed as a correlate of risk (CoR) of COVID-19. Peak and exposure-proximal titers were inverse CoRs with covariate-adjusted hazard ratios (95% confidence intervals) 0.30 (0.11, 0.78) and 0.25 (0.07, 0.85) per 10-fold increase in weighted average titer.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/cid/ciae465 | DOI Listing |
Publication Analysis
Top Keywords
neutralizing antibody
8
antibody immune
4
immune correlates
4
correlates recombinant
4
recombinant protein
4
protein vaccine
4
vaccine covail
4
covail trial
4
trial covail
4
covail recipients
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!